IP Library › Granted Patent US 12,618,060
Granted Patent B2
US 12,618,060 · App. 17/201,764 · Granted May 5, 2026

Nucleic acid molecules

Inventors: Mariola Fotin-Mleczek (Sindelfingen, DE); Katja Fiedler (Bad Urach, DE); Aleksandra Kowalczyk (Stuttgart, DE); Regina Heidenreich (Tübingen, DE)
Assignee: CureVac SE
C12N9/90A61K39/00A61K39/0011A61K39/385A61K39/39C07K14/70521C12Y503/03012A61K38/00A61K2039/53A61K2039/6031A61K2039/605C07K2319/02C07K2319/03
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,618,060
App. No.
17/201,764
Granted
May 5, 2026
Kind
B2
Abstract

The present invention provides novel artificial nucleic acid molecules encoding at least one antigenic peptide or protein and at least one additional sequence preferably targeting the antigenic peptides or proteins to cellular compartments of interest. Further, the invention provides (pharmaceutical) compositions or vaccines and kits comprising said nucleic acid molecules. The nucleic acid molecules, (pharmaceutical) compositions or vaccines and kits are useful for treating a variety of diseases such as cancer, infectious diseases, autoimmune diseases, allergies or graft-versus host disease.

Claims (27)

1 . An artificial RNA molecule comprising at least one coding region encoding

at least one antigenic protein comprising (i) at least one signal peptide, (ii) at least two epitopes from two different tumor antigens; (iii) a linker peptide linking said at least two epitopes,

and (iv) at least one transmembrane domain from CTLA4 (Cytotoxic T-lymphocyte protein 4).

2 . The artificial RNA molecule according to claim 1 , wherein said one of said at least two epitopes is from a tumor antigen selected from the group consisting of BRAF, PIK3CA, KRAS, IDH1, TP53, NRAS, AKTI, SF3B1, CDKN2A, RPSAP58, EGFR, NY-ESO1, MUC-1, 5T4, Her2, MAGE-A3, LY6K, CEACAM6, CEA, MCAK, KK-LC1, Gastrin, VEGFR2, MMP-7, MPHOSPH1, MAGE-A4, MAGE-A1, MAGE-C1, PRAME, Survivin, MAGE-A9, MAGE-C2, FGFR2, WT1, PSA, PSMA, Prostate-specific antigen precursor, Kita-kyushu lung cancer antigen 1, Trophoblast glycoprotein, Cyclin-dependent kinase inhibitor 2A, Cyclin-dependent kinase inhibitor 2A, isoforms 1/2/3, multiple tumor suppressor 1/cyclin-dependent kinase 4 inhibitor p16, GTPase, and NRas.

3 . The artificial RNA molecule according to claim 1 , wherein said at least one transmembrane domain from CTLA4 is identical to the transmembrane domain from SEQ ID NO: 169.

4 . The artificial RNA molecule according to claim 1 , wherein the linker peptide is 1-20 amino acids in length.

5 . The artificial RNA according to claim 4 , which comprises, in 5′ to 3′ direction, the following elements:

a) a 5′-CAP structure,

b) a 5′-UTR element,

c) said at least one coding region sequence,

d) a 3′-UTR element, and

e) a poly(A) tail.

6 . The artificial RNA according to claim 5 , wherein the linker peptide comprises the amino acid sequence Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 76409).

7 . The artificial RNA according to claim 6 , wherein the linker peptide consists of the amino acid sequence Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 76409).

8 . The artificial RNA according to claim 5 , wherein the at least one signal peptide is from CTLA4.

9 . The artificial RNA according to claim 8 , wherein said coding region further comprises at least one cytoplasmic domain of CTLA4.

10 . The artificial RNA according to claim 9 , wherein one of said at least two epitopes is from a tumor antigen selected from the group consisting of BRAF, PIK3CA, KRAS, IDH1, TP53, NRAS, AKTI, SF3B1, CDKN2A, RPSAP58, EGFR, NY-ESO1, MUC-1, 5T4, Her2, MAGE-A3, LY6K, CEACAM6, CEA, MCAK, KK-LC1, Gastrin, VEGFR2, MMP-7, MPHOSPH1, MAGE-A4, MAGE-A1, MAGE-C1, PRAME, Survivin, MAGE-A9, MAGE-C2, FGFR2, WT1, PSA, PSMA, Prostate-specific antigen precursor, Kita-kyushu lung cancer antigen 1, Trophoblast glycoprotein, Cyclin-dependent kinase inhibitor 2A, Cyclin-dependent kinase inhibitor 2A, isoforms 1/2/3, multiple tumor suppressor 1/cyclin-dependent kinase 4 inhibitor p16, GTPase, and NRas.

11 . The artificial RNA according to claim 9 , wherein one of said at least two epitopes is from a MAGE tumor antigen.

12 . The artificial RNA according to claim 9 , wherein the at least one coding region further comprises an epitope from a Hepatitis B virus antigen.

13 . The artificial RNA molecule according to claim 1 , wherein said at least one coding region further encodes

(v) at least one T helper epitope.

14 . The artificial RNA molecule according to claim 1 , wherein said artificial RNA molecule is a mRNA.

15 . A composition comprising at least one artificial RNA molecule according to claim 1 and a pharmaceutically acceptable carrier and/or excipient.

16 . The artificial RNA according to claim 1 , wherein said coding region further comprises at least one cytoplasmic domain of CTLA4.

17 . The artificial RNA according to claim 16 , wherein the at least one signal peptide comprises or consists of an amino acid sequence corresponding to any one of SEQ ID NOs: 1-156 or 76948-76951.

18 . The artificial RNA according to claim 1 , wherein one of said at least two epitopes is from KRAS.

19 . The artificial RNA according to claim 18 , wherein one of said at least two epitopes is a KRAS epitope having a mutation selected from the group consisting of A146T; G12A; G12C; G12D; G12F; G12R; G12S; G12V; G13C; G13D; K117N; Q61H; Q61K; Q61L; and Q61R.

Assignments (1)
CHANGE OF NAME Recorded Dec 28, 2022
From: CUREVAC AG
To: CUREVAC SE
Reel/Frame 062248/0954 →
Continuity (3)
Division 16026729 · Jul 3, 2018
Continuation PCTEP2017066676 · Jul 4, 2017
Related Publication 20210198649A1 · Jul 1, 2021
References Cited (307)
US 5633234A · August et al. · 1997 [cited by applicant]
US 7423023B2 · Boyle et al. · 2008 [cited by applicant]
US 8217016B2 · Hoerr et al. · 2012 [cited by applicant]
US 8383340B2 · Ketterer et al. · 2013 [cited by applicant]
US 8703906B2 · Baumhof et al. · 2014 [cited by applicant]
US 8968746B2 · Baumhof et al. · 2015 [cited by applicant]
US 9155788B2 · Hoerr et al. · 2015 [cited by applicant]
US 9226959B2 · Kramps et al. · 2016 [cited by applicant]
US 9234013B2 · Thess et al. · 2016 [cited by applicant]
US 9314535B2 · Baumhof et al. · 2016 [cited by applicant]
US 9352028B2 · Barner et al. · 2016 [cited by applicant]
US 9402887B2 · Probst et al. · 2016 [cited by applicant]
US 9421255B2 · Baumhof et al. · 2016 [cited by applicant]
US 9433669B2 · Hoerr et al. · 2016 [cited by applicant]
US 9433670B2 · Hoerr et al. · 2016 [cited by applicant]
US 9439956B2 · Hoerr et al. · 2016 [cited by applicant]
US 9447431B2 · Thess et al. · 2016 [cited by applicant]
US 9463228B2 · Hoerr et al. · 2016 [cited by applicant]
US 9572874B2 · Fotin-Mleczek et al. · 2017 [cited by applicant]
US 9616084B2 · Mutzke · 2017 [cited by applicant]
US 9623095B2 · Kallen et al. · 2017 [cited by applicant]
US 9655955B2 · Hoerr et al. · 2017 [cited by applicant]
US 9669089B2 · Thess et al. · 2017 [cited by applicant]
US 9683233B2 · Thess · 2017 [cited by applicant]
US 9688729B2 · Kramps et al. · 2017 [cited by applicant]
US 9737595B2 · Lorenz et al. · 2017 [cited by applicant]
US 9839697B2 · Thess et al. · 2017 [cited by applicant]
US 9890391B2 · Thess et al. · 2018 [cited by applicant]
US 9907862B2 · Baumhof et al. · 2018 [cited by applicant]
US 9974845B2 · Fotin-Mleczek et al. · 2018 [cited by applicant]
US 10010592B2 · Thess et al. · 2018 [cited by applicant]
US 10017826B2 · von der Mülbe et al. · 2018 [cited by applicant]
US 10047375B2 · Thess · 2018 [cited by applicant]
US 10080809B2 · Thess · 2018 [cited by applicant]
US 10111967B2 · Fotin-Mleczek et al. · 2018 [cited by applicant]
US 10111968B2 · Thess et al. · 2018 [cited by applicant]
US 10117920B2 · Fotin-Mleczek et al. · 2018 [cited by applicant]
US 10150797B2 · Kramps et al. · 2018 [cited by applicant]
US 10166283B2 · Thess et al. · 2019 [cited by applicant]
US 10172935B2 · Kallen et al. · 2019 [cited by applicant]
US 10188748B2 · von der Mülbe et al. · 2019 [cited by applicant]
US 10232024B2 · Thess et al. · 2019 [cited by applicant]
US 10293058B2 · Fotin-Mleczek et al. · 2019 [cited by applicant]
US 10293060B2 · Baumhof · 2019 [cited by applicant]
US 10307472B2 · Fotin-Mleczek et al. · 2019 [cited by applicant]
US 10369216B2 · Fotin-Mleczek et al. · 2019 [cited by applicant]
US 10434154B2 · Probst et al. · 2019 [cited by applicant]
US 10434158B2 · Fotin-Mleczek et al. · 2019 [cited by applicant]
US 10441653B2 · Hoerr et al. · 2019 [cited by applicant]
US 10501768B2 · Eber et al. · 2019 [cited by applicant]
US 10517827B2 · Eber et al. · 2019 [cited by applicant]
US 10568958B2 · Baumhof et al. · 2020 [cited by applicant]
US 10568972B2 · von der Mülbe et al. · 2020 [cited by applicant]
US 10588959B2 · Kallen et al. · 2020 [cited by applicant]
US 10596252B2 · Kallen et al. · 2020 [cited by applicant]
US 10610605B2 · Thess et al. · 2020 [cited by applicant]
US 10648017B2 · Wochner · 2020 [cited by applicant]
US 10653768B2 · Mutzke et al. · 2020 [cited by applicant]
US 10653799B2 · Thess et al. · 2020 [cited by applicant]
US 10682406B2 · Thess et al. · 2020 [cited by applicant]
US 10682426B2 · Schnee et al. · 2020 [cited by applicant]
US 10711315B2 · von der Mülbe et al. · 2020 [cited by applicant]
US 10729654B2 · Eber et al. · 2020 [cited by applicant]
US 10729761B2 · Kallen et al. · 2020 [cited by applicant]
US 10738306B2 · Thess · 2020 [cited by applicant]
US 10751424B2 · Baumhof et al. · 2020 [cited by applicant]
US 10760070B2 · Funkner et al. · 2020 [cited by applicant]
US 10780054B2 · Ketterer et al. · 2020 [cited by applicant]
US 10799577B2 · Thess et al. · 2020 [cited by applicant]
US 10799602B2 · Baumhof · 2020 [cited by applicant]
US 10837039B2 · Wochner et al. · 2020 [cited by applicant]
US 10869935B2 · Fotin-Mleczek et al. · 2020 [cited by applicant]
US 10898584B2 · Schlake et al. · 2021 [cited by applicant]
US 10898589B2 · Thess et al. · 2021 [cited by applicant]
US 10912826B2 · Thess et al. · 2021 [cited by applicant]
US 10918740B2 · Fotin-Mleczek et al. · 2021 [cited by applicant]
US 10988754B2 · Fotin-Mleczek et al. · 2021 [cited by applicant]
US 11034729B2 · Kramps et al. · 2021 [cited by applicant]
US 11078247B2 · Fotin-Mleczek et al. · 2021 [cited by applicant]
US 11110156B2 · Thess et al. · 2021 [cited by applicant]
US 11110157B2 · Fotin-Mleczek et al. · 2021 [cited by applicant]
US 11110166B2 · Fotin-Mleczek et al. · 2021 [cited by applicant]
US 11135312B2 · von der Mülbe et al. · 2021 [cited by applicant]
US 11141474B2 · Rauch et al. · 2021 [cited by applicant]
US 11141476B2 · Rauch · 2021 [cited by applicant]
US 11149278B2 · Thess et al. · 2021 [cited by applicant]
US 11179337B2 · Eber et al. · 2021 [cited by applicant]
US 11225682B2 · Reichert et al. · 2022 [cited by applicant]
US 11241493B2 · Rauch et al. · 2022 [cited by applicant]
US 11248223B2 · Yazdan Panah et al. · 2022 [cited by applicant]
US 11254951B2 · Thess · 2022 [cited by applicant]
US 11266735B2 · Kallen et al. · 2022 [cited by applicant]
US 11268157B2 · von der Mülbe et al. · 2022 [cited by applicant]
US 20030091590A1 · Pomerantz et al. · 2003 [cited by applicant]
US 20050032730A1 · von der Mülbe et al. · 2005 [cited by applicant]
US 20050059624A1 · Hoerr et al. · 2005 [cited by applicant]
US 20050250723A1 · Hoerr et al. · 2005 [cited by applicant]
US 20060188490A1 · Hoerr et al. · 2006 [cited by applicant]
US 20070048301A1 · Bodary-Winter et al. · 2007 [cited by applicant]
US 20070224208A1 · Guo et al. · 2007 [cited by applicant]
US 20070280929A1 · Hoerr et al. · 2007 [cited by applicant]
US 20080025944A1 · Hoerr et al. · 2008 [cited by applicant]
US 20080171711A1 · Hoerr et al. · 2008 [cited by applicant]
US 20080267873A1 · Hoerr et al. · 2008 [cited by applicant]
US 20090324584A1 · Hoerr et al. · 2009 [cited by applicant]
US 20100047261A1 · Hoerr et al. · 2010 [cited by applicant]
US 20100048883A1 · Ketterer et al. · 2010 [cited by applicant]
US 20100111993A1 · Tuereci et al. · 2010 [cited by applicant]
US 20100189729A1 · Hoerr et al. · 2010 [cited by applicant]
US 20100203076A1 · Fotin-Mleczek et al. · 2010 [cited by applicant]
US 20100291156A1 · Barner et al. · 2010 [cited by applicant]
US 20100305196A1 · Probst et al. · 2010 [cited by applicant]
US 20110053829A1 · Baumhof et al. · 2011 [cited by applicant]
US 20110250225A1 · Fotin-Mleczek et al. · 2011 [cited by applicant]
US 20120021043A1 · Kramps et al. · 2012 [cited by applicant]
US 20120258046A1 · Mutzke · 2012 [cited by applicant]
US 20130129754A1 · Thess et al. · 2013 [cited by applicant]
US 20130142818A1 · Baumhof et al. · 2013 [cited by applicant]
US 20130195867A1 · Hoerr et al. · 2013 [cited by applicant]
US 20130259879A1 · Baumhof et al. · 2013 [cited by applicant]
US 20130280283A1 · Lorenz et al. · 2013 [cited by applicant]
US 20130282083A1 · Vertikov et al. · 2013 [cited by applicant]
US 20130295043A1 · Kallen et al. · 2013 [cited by applicant]
US 20130336998A1 · Kallen et al. · 2013 [cited by applicant]
US 20150037326A1 · Butler-Ransohoff et al. · 2015 [cited by applicant]
US 20150050302A1 · Thess · 2015 [cited by applicant]
US 20150057340A1 · Thess et al. · 2015 [cited by applicant]
US 20150093413A1 · Thess et al. · 2015 [cited by applicant]
US 20150118183A1 · Baumhof · 2015 [cited by applicant]
US 20150118264A1 · Baumhof et al. · 2015 [cited by applicant]
US 20150165006A1 · Thess et al. · 2015 [cited by applicant]
US 20150184195A1 · Thess et al. · 2015 [cited by applicant]
US 20150218554A1 · Thess · 2015 [cited by applicant]
US 20150258214A1 · Baumhof et al. · 2015 [cited by applicant]
US 20150306249A1 · Baumhof et al. · 2015 [cited by applicant]
US 20150320847A1 · Thess et al. · 2015 [cited by applicant]
US 20160129105A1 · von der Mülbe et al. · 2016 [cited by applicant]
US 20160130345A1 · Fotin-Mleczek et al. · 2016 [cited by applicant]
US 20160166668A1 · Kallen et al. · 2016 [cited by applicant]
US 20160166678A1 · Kallen et al. · 2016 [cited by applicant]
US 20160166710A1 · Baumhof · 2016 [cited by applicant]
US 20160166711A1 · Schnee et al. · 2016 [cited by applicant]
US 20160168207A1 · Kramps et al. · 2016 [cited by applicant]
US 20160168227A1 · Kallen et al. · 2016 [cited by applicant]
US 20160235864A1 · Schlake et al. · 2016 [cited by applicant]
US 20160304883A1 · Grund et al. · 2016 [cited by applicant]
US 20160304938A1 · Wochner · 2016 [cited by applicant]
US 20160326575A1 · von der Mülbe et al. · 2016 [cited by applicant]
US 20160331844A1 · Fotin-Mleczek et al. · 2016 [cited by applicant]
US 20170014496A1 · Fotin-Mleczek et al. · 2017 [cited by applicant]
US 20170029847A1 · Thess · 2017 [cited by applicant]
US 20170114378A1 · Wochner et al. · 2017 [cited by applicant]
US 20170252430A1 · Fotin-Mleczek et al. · 2017 [cited by applicant]
US 20170326225A1 · Rauch et al. · 2017 [cited by applicant]
US 20180044687A1 · Thess et al. · 2018 [cited by applicant]
US 20180125952A1 · Fotin-Mleczek et al. · 2018 [cited by applicant]
US 20180126003A1 · Hoerr · 2018 [cited by applicant]
US 20180142275A1 · Roos et al. · 2018 [cited by applicant]
US 20180147146A1 · Eber et al. · 2018 [cited by applicant]
US 20180148727A1 · Grund et al. · 2018 [cited by applicant]
US 20180201967A1 · Eber et al. · 2018 [cited by applicant]
US 20180208957A1 · Roos et al. · 2018 [cited by applicant]
US 20180214537A1 · Mutzke et al. · 2018 [cited by applicant]
US 20180237786A1 · Schlake et al. · 2018 [cited by applicant]
US 20180237817A1 · Roos et al. · 2018 [cited by applicant]
US 20180243219A1 · Ketterer et al. · 2018 [cited by applicant]
US 20180296663A1 · Hipp et al. · 2018 [cited by applicant]
US 20180298372A1 · Funkner et al. · 2018 [cited by applicant]
US 20180312545A1 · Baumhof et al. · 2018 [cited by applicant]
US 20180371392A1 · Mayer et al. · 2018 [cited by applicant]
US 20190010485A1 · Yazdan Panah et al. · 2019 [cited by applicant]
US 20190017100A1 · Wochner et al. · 2019 [cited by applicant]
US 20190024096A1 · Schmid et al. · 2019 [cited by applicant]
US 20190049414A1 · Wochner et al. · 2019 [cited by applicant]
US 20190083602A1 · Roos et al. · 2019 [cited by applicant]
US 20190100784A1 · Eber et al. · 2019 [cited by applicant]
US 20190125857A1 · Rauch et al. · 2019 [cited by applicant]
US 20190133950A1 · Eber et al. · 2019 [cited by applicant]
US 20190177714A1 · Kunze et al. · 2019 [cited by applicant]
US 20190185859A1 · Fotin-Mleczek et al. · 2019 [cited by applicant]
US 20190194760A1 · Koch et al. · 2019 [cited by applicant]
US 20190225971A1 · Williams · 2019 [cited by applicant]
US 20190241633A1 · Fotin-Mleczek et al. · 2019 [cited by applicant]
US 20190241925A1 · Hishiya · 2019 [cited by applicant]
US 20190249219A1 · Reichert et al. · 2019 [cited by applicant]
US 20190336608A1 · Baumhof et al. · 2019 [cited by applicant]
US 20190336611A1 · Baumhof et al. · 2019 [cited by applicant]
US 20190343933A1 · Horscroft et al. · 2019 [cited by applicant]
US 20190343942A1 · Fotin-Mleczek et al. · 2019 [cited by applicant]
US 20190351044A1 · Jasny et al. · 2019 [cited by applicant]
US 20190351047A1 · Jasny et al. · 2019 [cited by applicant]
US 20190381180A1 · Baumhof et al. · 2019 [cited by applicant]
US 20200023076A1 · Fotin-Mleczek et al. · 2020 [cited by applicant]
US 20200085852A1 · Fotin-Mleczek · 2020 [cited by applicant]
US 20200085944A1 · Heidenreich et al. · 2020 [cited by applicant]
US 20200149026A1 · Horscroft et al. · 2020 [cited by applicant]
US 20200163878A1 · Baumhof et al. · 2020 [cited by applicant]
US 20200179526A1 · Baumhof et al. · 2020 [cited by applicant]
US 20200392572A1 · Yazdan Panah et al. · 2020 [cited by applicant]
US 20210030864A1 · Petsch et al. · 2021 [cited by applicant]
US 20210069315A1 · Baumhof et al. · 2021 [cited by applicant]
US 20210162037A1 · Jasny et al. · 2021 [cited by applicant]
US 20210170017A1 · Lutz et al. · 2021 [cited by applicant]
US 20210180106A1 · Wochner et al. · 2021 [cited by applicant]
US 20210205434A1 · Petsch et al. · 2021 [cited by applicant]
US 20210260178A1 · Jasny et al. · 2021 [cited by applicant]
US 20210261897A1 · Yazdan Panah et al. · 2021 [cited by applicant]
US 20210361761A1 · Lutz et al. · 2021 [cited by applicant]
US 20210403925A1 · Chevessier-Tünnesen et al. · 2021 [cited by applicant]
US 20220040281A1 · Schwendt et al. · 2022 [cited by applicant]
US 20220073962A1 · Schwenger et al. · 2022 [cited by applicant]
JP 2005535627 · 2005 [cited by applicant]
JP 2012522802 · 2012 [cited by applicant]
WO WO1999058658 · 1999 [cited by applicant]
WO WO2002085434 · 2002 [cited by applicant]
WO WO2002085933 · 2002 [cited by applicant]
WO WO2003059381 · 2003 [cited by applicant]
WO WO2004000873 · 2003 [cited by applicant]
WO WO2007024708 · 2007 [cited by applicant]
WO WO2009127230 · 2009 [cited by applicant]
WO WO2010088927 · 2010 [cited by applicant]
WO WO2010115046 · 2010 [cited by applicant]
WO WO2011069528 · 2011 [cited by applicant]
WO WO2011069587 · 2011 [cited by applicant]
WO WO2011144358 · 2011 [cited by applicant]
WO WO2012031043 · 2012 [cited by applicant]
WO WO2012116714 · 2012 [cited by applicant]
WO WO2012116715 · 2012 [cited by applicant]
WO WO2013019615A2 · 2013 [cited by examiner]
WO WO2013033563 · 2013 [cited by applicant]
WO WO2014100385 · 2014 [cited by applicant]
WO WO2015024666 · 2015 [cited by applicant]
WO WO2015062738 · 2015 [cited by applicant]
WO WO2015082922 · 2015 [cited by applicant]
WO WO2015100219 · 2015 [cited by applicant]
WO WO2015101414 · 2015 [cited by applicant]
WO WO2015101415 · 2015 [cited by applicant]
WO WO2015101416 · 2015 [cited by applicant]
WO WO2015112626A1 · 2015 [cited by examiner]
WO WO2015135558 · 2015 [cited by applicant]
WO WO2015149944 · 2015 [cited by applicant]
WO WO2015188933 · 2015 [cited by applicant]
WO WO2016044605 · 2016 [cited by applicant]
WO WO2016091391 · 2016 [cited by applicant]
WO WO2016097065 · 2016 [cited by applicant]
WO WO2016107877 · 2016 [cited by applicant]
WO WO2016165825 · 2016 [cited by applicant]
WO WO2016165831 · 2016 [cited by applicant]
WO WO2016170176 · 2016 [cited by applicant]
WO WO2016174227 · 2016 [cited by applicant]
WO WO2016174271 · 2016 [cited by applicant]
WO WO2016180430 · 2016 [cited by applicant]
WO WO2016184575 · 2016 [cited by applicant]
WO WO2016184576 · 2016 [cited by applicant]
WO WO2016184577 · 2016 [cited by applicant]
WO WO2016184822 · 2016 [cited by applicant]
WO WO2016193206 · 2016 [cited by applicant]
WO WO2016193226 · 2016 [cited by applicant]
WO WO2016203025 · 2016 [cited by applicant]
WO WO2017001058 · 2017 [cited by applicant]
WO WO2017009376 · 2017 [cited by applicant]
WO WO2017021546 · 2017 [cited by applicant]
WO WO2017025120 · 2017 [cited by applicant]
WO WO2017025447 · 2017 [cited by applicant]
WO WO2017036580 · 2017 [cited by applicant]
WO WO2017064146 · 2017 [cited by applicant]
WO WO2017081082 · 2017 [cited by applicant]
WO WO2017081110 · 2017 [cited by applicant]
WO WO2017108087 · 2017 [cited by applicant]
WO WO2017109134 · 2017 [cited by applicant]
WO WO2017109161 · 2017 [cited by applicant]
WO WO2017137095 · 2017 [cited by applicant]
WO WO2017140905 · 2017 [cited by applicant]
WO WO2017162297 · 2017 [cited by applicant]
WO WO2017182634 · 2017 [cited by applicant]
WO WO2017186928 · 2017 [cited by applicant]
WO WO2017191258 · 2017 [cited by applicant]
WO WO2017191274 · 2017 [cited by applicant]
WO WO2017203008 · 2017 [cited by applicant]
WO WO2017212006 · 2017 [cited by applicant]
WO WO2017212007 · 2017 [cited by applicant]
WO WO2017212008 · 2017 [cited by applicant]
WO WO2017212009 · 2017 [cited by applicant]
WO WO2018033254 · 2018 [cited by applicant]
WO WO2018078053 · 2018 [cited by applicant]
Peggs et al., Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of antiCTLA-4 antibodies (JEM, 2009, 206:1717-1725) (Year: 2009). [cited by examiner]
Laurent et al. The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-α production (J Trans Med, 2013, 1:108) (Year: 2013). [cited by examiner]
Fontana et al. Peripheral blood lymphocytes genetically modified to express the self/tumor antigen MAGE-A3 induce antitumor immune responses in cancer patients (Blood, 2009, 113:1651-1660) (Year: 2009). [cited by examiner]
Signor et al. DNA vaccination strategies for anti-tumour effective gene therapy protocols (Cancer Immunol Immunother, 2010, 59:1583-1591) (Year: 2010). [cited by examiner]
Sigalov, “New therapeutic strategies targeting transmembrane signal transduction in the immune system,” Cell Adhesion & Migration, 4:255-267, 2010. [cited by applicant]
Sigalov, “The School of nature: III. From mechanistic understanding to novel therapies,” Self/Nonself, 1:192-224, 2010. [cited by applicant]
Bonifacino et al., “Signals for Sorting of Transmembrane Proteins to Endosomes and Lysosomes,” [cited by applicant]
Boyle et al., “Enhanced responses to a DNA vaccine encoding a fusion antigen that is directed to sites of immune induction,” [cited by applicant]
Deliyannis et al., “A fusion DNA vaccine that targets antigen-presenting cells increases protection from viral challenge,” [cited by applicant]
Fiedler et al., “mRNA Cancer Vaccines,” In: [cited by applicant]
Huang et al., “Enhanced antitumor immunity by fusion of CTLA-4 to a self tumor antigen,” Blood, 96:3663-3670, 2000. [cited by applicant]
International Search Report and Written Opinion issued in corresponding PCT Application No. PCT/EP2018/068015, mailed on Oct. 22, 2018. [cited by applicant]
Kallen et al., “A novel, disruptive vaccination technology: self-adjuvanced RNActive® vaccines,” [cited by applicant]
Kübler et al., “Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study,” [cited by applicant]
Office Communication issued in U.S. Appl. No. 16/026,729, mailed Sep. 4, 2019. [cited by applicant]
Office Communication issued in U.S. Appl. No. 16/026,729, mailed Jan. 30, 2020. [cited by applicant]
Office Communication issued in U.S. Appl. No. 16/026,729, mailed Oct. 5, 2020. [cited by applicant]
Office Communication issued in U.S. Appl. No. 16/026,729, mailed Dec. 16, 2020. [cited by applicant]
Weng et al., “DNA vaccine elicits an efficient antitumor response by targeting the mutant Kras in a transgenic mouse lung cancer model,” Gene Therapy, 21:888-896, 2014. [cited by applicant]
Xu et al., “Analysis of the molecular mechanisms of targeted anti-caries DNA plasmid enhancing antibody responses by gene arrays,” [cited by applicant]
Chakraborty et al., “Ras proteins as therapeutic targets,” [cited by applicant]
Ostrem et al., “K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions,” [cited by applicant]